CytoReason
@Cytoreason
Followers
596
Following
312
Media
138
Statuses
574
CytoReason’s computational disease model, used by 5/10 top pharma leaders, minimizes need for animal trials and makes human trials more accurate and focused.
Israel
Joined February 2018
שבוע טוב @TalMeir2, אני מבינה שחששת להביא אותי לראיון שבו אני גם מדברת, אז בחרת במונולוג מוכתב. אשמח להגיע מתי שתרצי לאולפן ולדון באופן ענייני, שיכבד את הקהל שלך וייתן לו להחליט בעצמו מה נכון. אם, ועד שתעיזי לנהל איתי דיון ענייני - רציתי להודות לך על הפרגון על התמונה בעיתון
76
73
1K
CytoReason is #hiring. We're looking for #backend and #fullstack developers, #bioinformaticians, #immunologists and more. Find out more and apply here: https://t.co/QsTWRyyrec
0
0
1
Tania Dubovik Perets with Elina Starosvetsky, Yasmin Admon, Shai @shenorr & others publish groundbreaking study showing immune system’s adaptability and providing evidence that interactions between immune cell types facilitate evolution of immune traits. https://t.co/WojqQPIY7L
0
0
3
CytoReason raises $80M in Series B from @nvidia, @pfizer, @thermofisher and others. This means we'll be able to cover more sub-populations, strengthen precision of our disease models and empower more decision-makers with AI tools for their R&D. https://t.co/8Lo9GXeGyR
0
0
1
Read more about CytoReason's new data collaboration agreement with @CrohnsColitisFn. We'll be integrating the foundation's vast datasets with CytoReason’s #IBD disease models. Read more about it here: https://t.co/79JVPilFhY
0
0
2
@Cytoreason signs data collaboration with @CrohnsColitisFn Foundation to advance IBD. We'll be incorporating CCF's massive datasets - with thousands of patient intestinal biopsies and comprehensive real-world data - into our pre-computed disease models. https://t.co/p00hjp2D2Y
0
0
2
New episode of "Tech on Drugs" with Prof. Eran Segal from Weizmann and co-founder Prof. Shai @shenorr - addressing precision nutrition, large-scale longitudinal data, microbiome studies, and more. Fulle episode here: https://t.co/tWavNelxqO
0
0
1
In 2023 - 21 CytoReason employees, published 19 papers in 16 different publications - Nature Immunology, Nature Cancer, Nature Communications, Nucleic Acids Research, CellReports, &more. More here: https://t.co/Ol8gqXN4vh
#Immunology #pharma
@CellReports
@NAR_Open
0
0
3
Interview with CEO David Harel about some of the major scientific and commercial challenges our industry faces, and about one tech company's attempt to make things (a little bit) better. https://t.co/brK2L0b5TH
0
1
2
Proud of our Chief Scientist Shai @shenorr for contributing to this new study by Benguigui & Cooper et. al, now published in Cancer Cell and highlighted in Nature Reviews Immunology. https://t.co/Zi3pgkAKjJ
#CancerResearch #Oncology
cell.com
A lack of reliable, highly predictive biomarkers remains a major obstacle in immuno-oncology. In this study, Benguigui et al. discover a promising new biomarker: interferon-stimulated, Ly6Ehi...
0
2
3
Our team's research published in @CellReports. Introducing 'Disruption Networks', a personalized computational network framework for system-level understanding of disease mechanisms & drug response, exposing differential regulation @ individual level. https://t.co/1oNWzdjV1V
cell.com
Biologic therapies show suboptimal responses, with high inter-patient heterogeneity hindering response biomarker identification. “Disruption Networks” monitor how each individual’s molecular network...
0
3
4
Another TOD episode is out! This time with serial biotech entrepreneur @YanayOfran. Yanay spoke to Shai @shenorr about the barriers to #PrecisionMedicine and about the power of AI-designed antibodies. https://t.co/tWavNelxqO
#biotech #drugdiscovery
0
1
2
In this episode of "Tech on Drugs (TOD), our Chief Medical Officer Yehuda Chowers talks about immunogenicity, population models, and the next generation of drug development. https://t.co/tWavNem5gm
#Biotechnology #Pharmaceutical
cytoreason.com
TECH ON DRUGS A podcast about pharma’s digital transformation Read More > Episode 1 Tech on Drugs – Episode 1 – Ran Balicer Our first episode features world renowned epidemiologist, Prof. Ran...
0
0
4
We're expanding our partnership with @Sanofi to a multiyear, multimillion dollar collaboration. Joining forces to bring precision medicine to #IBD! https://t.co/LvqW5sNkzC
biospace.com
Sanofi licensed CytoReason's inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.
0
0
7
Our new podcast "Tech on Drugs" is live. Host Shai @shenorr speaks to top scientists and execs about #pharma's digital transformation. First guest - renowned epidemiologist @RanBalicer. https://t.co/tWavNelxqO
#biotech #Pharmaceutical #DrugDiscovery
0
1
6
#2022 was the year we scaled up. Here are some highlights. Can't wait for 2023! #Biotech #Pharmaceutical #AI
0
2
6
Using our computational disease models to evaluate novel disease mechanisms for #influenza with @PoolbegPharma. Potential to yield drug targets for treatments more efficiently than with traditional reductionist analysis & #drugdiscovery techniques. https://t.co/ecVdyQxhEW
0
2
6
The construction of the tailored #AI influenza disease model has been completed by @Cytoreason using #POLB’s unique human challenge trial data 🔬unlock meaningful insights into #flu infection & recovery 💊 allow identification of novel flu drug targets https://t.co/kJJUO2C56o
1
9
14
At the Human Vaccine Project's summit, our Chief Scientist Shai @shenorr joined forces with world-leading scientists to promote efforts to decode and model the entire immune system. https://t.co/OQ3OExETdB
#Immunology #biotech #Pharmaceutical #vaccine
0
0
2
CytoReason’s computational disease models map and compare treatments, patient groups and disease mechanisms all in one. Learn more about how we use cell-level and network analysis to understand the different layers of human disease here: https://t.co/AtwRCVsON7
0
0
2